MYRIAD GENETICS INC (MYGN)
US62855J1043 - Common Stock
Overall MYGN gets a fundamental rating of 3 out of 10. We evaluated MYGN against 588 industry peers in the Biotechnology industry. MYGN may be in some trouble as it scores bad on both profitability and health. MYGN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MYGN has reported negative net income.
In the past year MYGN has reported a negative cash flow from operations.
In the past 5 years MYGN reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: MYGN reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -22.97%, MYGN is in the better half of the industry, outperforming 78.77% of the companies in the same industry.
The Return On Equity of MYGN (-33.62%) is better than 79.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.97% | ||
| ROE | -33.62% | ||
| ROIC | N/A |
ROA(3y)-11.46%
ROA(5y)-9.66%
ROE(3y)-16.36%
ROE(5y)-14.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MYGN has a better Gross Margin (68.64%) than 83.73% of its industry peers.
MYGN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MYGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-2.06%
2. Health
2.1 Basic Checks
MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYGN has been increased compared to 1 year ago.
Compared to 5 years ago, MYGN has more shares outstanding
MYGN has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.33 indicates that MYGN is not a great score, but indicates only limited risk for bankruptcy at the moment.
MYGN's Altman-Z score of 2.33 is fine compared to the rest of the industry. MYGN outperforms 73.63% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that MYGN is not too dependend on debt financing.
The Debt to Equity ratio of MYGN (0.05) is worse than 60.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.33 |
ROIC/WACCN/A
WACC9.25%
2.3 Liquidity
A Current Ratio of 2.01 indicates that MYGN has no problem at all paying its short term obligations.
MYGN's Current ratio of 2.01 is on the low side compared to the rest of the industry. MYGN is outperformed by 77.23% of its industry peers.
MYGN has a Quick Ratio of 1.87. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.87, MYGN is not doing good in the industry: 76.20% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.01 | ||
| Quick Ratio | 1.87 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 6.67% over the past year.
Looking at the last year, MYGN shows a quite strong growth in Revenue. The Revenue has grown by 11.03% in the last year.
MYGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.25% yearly.
EPS 1Y (TTM)6.67%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q133.33%
Revenue 1Y (TTM)11.03%
Revenue growth 3Y5.66%
Revenue growth 5Y0.25%
Revenue growth Q2Q10.57%
3.2 Future
MYGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 63.03% yearly.
The Revenue is expected to grow by 8.88% on average over the next years. This is quite good.
EPS Next Y108.21%
EPS Next 2Y69.71%
EPS Next 3Y51.6%
EPS Next 5Y63.03%
Revenue Next Year10.03%
Revenue Next 2Y9.13%
Revenue Next 3Y8.6%
Revenue Next 5Y8.88%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MYGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 792.71, which means the current valuation is very expensive for MYGN.
Based on the Price/Forward Earnings ratio, MYGN is valued cheaper than 93.66% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of MYGN to the average of the S&P500 Index (21.63), we can say MYGN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 792.71 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MYGN does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as MYGN's earnings are expected to grow with 51.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.71%
EPS Next 3Y51.6%
5. Dividend
5.1 Amount
MYGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MYRIAD GENETICS INC
NASDAQ:MYGN (4/26/2024, 11:47:50 AM)
18.225
+0.25 (+1.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.64B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 792.71 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.97% | ||
| ROE | -33.62% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.64% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.01 | ||
| Quick Ratio | 1.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)6.67%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y108.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.03%
Revenue growth 3Y5.66%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y